BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 12749268)

  • 21. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53.
    Rady PL; Schnadig VJ; Weiss RL; Hughes TK; Tyring SK
    Laryngoscope; 1998 May; 108(5):735-40. PubMed ID: 9591556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
    Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
    Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas.
    Izawa T; Obara T; Tanno S; Mizukami Y; Yanagawa N; Kohgo Y
    Cancer; 2001 Oct; 92(7):1807-17. PubMed ID: 11745253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
    Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
    Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K-ras mutation in focal proliferative lesions of human pancreas.
    Terhune PG; Phifer DM; Tosteson TD; Longnecker DS
    Cancer Epidemiol Biomarkers Prev; 1998 Jun; 7(6):515-21. PubMed ID: 9641496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
    de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations.
    Gansauge S; Schmid RM; Muller J; Adler G; Mattfeldt T; Beger HG
    Br J Surg; 1998 Mar; 85(3):337-40. PubMed ID: 9529487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation.
    Yamaguchi Y; Watanabe H; Yrdiran S; Ohtsubo K; Motoo Y; Okai T; Sawabu N
    Clin Cancer Res; 1999 May; 5(5):1147-53. PubMed ID: 10353750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular diagnosis of pancreatic cancer].
    Sugano K
    Nihon Geka Gakkai Zasshi; 1997 Jul; 98(7):597-603. PubMed ID: 9276865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
    Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
    Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.
    Erill N; Cuatrecasas M; Sancho FJ; Farré A; Pour PM; Lluís F; Capellá G
    Am J Pathol; 1996 Oct; 149(4):1333-9. PubMed ID: 8863680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.
    Nindl I; Gottschling M; Krawtchenko N; Lehmann MD; Röwert-Huber J; Eberle J; Stockfleth E; Forschner T
    Br J Dermatol; 2007 May; 156 Suppl 3():34-9. PubMed ID: 17488404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical analysis of expression of molecular biologic factors in intraductal papillary-mucinous tumors of pancreas--diagnostic and biologic significance.
    Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
    Hepatogastroenterology; 1999; 46(28):2599-605. PubMed ID: 10522048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis.
    Löhr M; Müller P; Mora J; Brinkmann B; Ostwald C; Farré A; Lluis F; Adam U; Stubbe J; Plath F; Nizze H; Hopt UT; Barten M; Capellá G; Liebe S
    Gastrointest Endosc; 2001 Jun; 53(7):734-43. PubMed ID: 11375580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas.
    Raimondo M; Tachibana I; Urrutia R; Burgart LJ; DiMagno EP
    Am J Gastroenterol; 2002 Oct; 97(10):2553-8. PubMed ID: 12385438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts.
    Soldini D; Gugger M; Burckhardt E; Kappeler A; Laissue JA; Mazzucchelli L
    J Pathol; 2003 Apr; 199(4):453-61. PubMed ID: 12635136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.